GlassScriptPhysician profile
Luis A Soro
NPI 1649585639
$307,007.10
in general payments reported to CMS, 2019-2025
11 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $36K · 2021: $42K · 2022: $99K · 2023: $37K · 2024: $31K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $84K · Travel and Lodging: $3,325 · Food and Beverage: $2,014 · Consulting Fee: $800 · Education: $5.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $83,709.69 |
| Travel and Lodging | $3,325.49 |
| Food and Beverage | $2,013.70 |
| Consulting Fee | $800.00 |
| Education | $5.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $116,064.80 | 2019-2022 | |
| Galderma Laboratories, L.P. | $100,831.64 | 2019-2025 | Dysport |
| Abbvie INC. | $66,358.40 | 2023-2025 | Botox, Kybella |
| Merz North America, INC. | $23,167.12 | 2019-2024 | Xeomin |
| Revance Therapeutics, INC. | $292.95 | 2024-2025 | Daxxify |
| Musculoskeletal Transplant Foundation INC. | $185.53 | 2022-2025 | |
| Biofrontera INC. | $26.50 | 2019 | |
| Leo Pharma INC. | $23.20 | 2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.96 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $19.61 | 2024 | Clear+Brilliant |
| Pierre Fabre Pharmaceuticals, INC. | $17.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Soro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.